Reports
Sale
Global Mammalian Polyclonal IgG Antibody Market Size, Growth: By Product: Cardiac Makers, Metabolic Markers, Renal Markers, Others; By Applications: ELISA, Immunoturbidometry, Immunoelectrophoresis, Others; By End User: Hospitals, Diagnostic Centres, Academic and Research Institutes; Regional Analysis; Supplier Landscape; 2024-2032
Global Mammalian Polyclonal IgG Antibody Market Outlook
The global mammalian polyclonal IgG antibody market size was valued at USD 1.16 billion in 2023, driven by the increasing demand in drug and diagnostics across the globe. The market size is anticipated to grow at a CAGR of 5.3% during the forecast period of 2024-2032 to achieve a value of USD 1.84 billion by 2032.
Mammalian Polyclonal IgG Antibody: Introduction
Mammalian polyclonal IgG antibodies are a class of immunoglobulins produced by the immune system of mammals, including humans. They are composed of a mixture of antibodies that recognize different epitopes on an antigen. Polyclonal antibodies are derived from the serum or plasma of immunized animals or humans and are widely used in various research, diagnostic, and therapeutic applications. Some of the major features of mammalian polyclonal igg antibodies include diverse specificity, enhanced sensitivity, isotype, natural production, research and diagnostics, and therapeutic applications, among others.
Global Mammalian Polyclonal IgG Antibody Market Analysis
The increasing demand for mammalian polyclonal IgG antibodies in research and diagnostics is propelling the market growth as these antibodies are widely used in research, diagnostics, and therapeutic applications. The demand for these antibodies is being driven in many research and diagnostic contexts by the growing emphasis on understanding disease mechanisms, biomarker identification, and personalized therapy. With the rising development of biologics and antibody-based therapeutics , the biopharmaceutical industry is expanding quickly. This is also fuelling the global mammalian polyclonal IgG antibody market growth as these antibodies are essential for preclinical and clinical research on target validation, antibody characterization, and assay development.
A study was published earlier this year on MDPI platform about the effectiveness of polyclonal antibodies derived from trans chromosomic bovines vaccinated with the recombinant F1-V vaccine in protecting mice from pneumonic plague. The study shows promising results in increasing bacterial opsonization in vitro and provides hope for potential future treatments. This study also showed potential in reduction of discovery costs by expediting the screening process, reducing the time required for initial evaluation. The study also aimed to use the antibodies as benchmarks to be used later in rapidly screen potential novel antibody therapeutics directed against F1 or LcrV antigens further contributing to the global mammalian polyclonal IgG antibody market share.
Increased investment from both public and private sectors in antibody research and development is driving innovation in the field. Funding initiatives, collaborations, and partnerships are supporting the discovery of novel antibodies, advancements in production technologies, and expansion of antibody-based applications, thereby fueling the growth of the market.
Global Mammalian Polyclonal IgG Antibody Market Segmentations
Market Breakup by Product
- Cardiac Makers
- Metabolic Markers
- Renal Markers
- Others
Market Breakup by Applications
- ELISA
- Immunoturbidometry
- Immunoelectrophoresis
- Antibody Identification
- Immunohistochemistry
- Immunocytochemistry
- Western Blotting
Market Breakup by End User
- Hospitals
- Diagnostic Centres
- Academic and Research Institutes
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Global Mammalian Polyclonal IgG Antibody Market Overview
The biopharmaceutical industry is experiencing significant growth due to the increasing focus on the development of antibody-based therapeutics. The increasing prevalence of chronic and infectious diseases is also driving the demand for research on disease mechanisms, biomarker discovery, and therapeutic methods. The use of therapeutic treatments and biopharmaceuticals has been transformed by monoclonal antibodies. Mammalian polyclonal IgG antibodies nonetheless continue to be very useful in research and development, particularly in the early stages of study, target validation, and assay development.
The mammalian polyclonal IgG antibody market demand is influenced by the ongoing improvements in monoclonal antibody development, along with the rising requirement for comparative research using polyclonal antibodies. The importance of personalised treatment choices that are suited to specific patient characteristics is highlighted by the growing emphasis on personalised medicine and precision healthcare.
Advancement in antibody production technologies, including transgenic animal platforms, hybridoma-based approaches, and recombinant DNA techniques, have improved the efficiency, scalability, and quality of mammalian polyclonal IgG antibody production. These technological advancements have reduced production times, enhanced antibody yields, and made mammalian polyclonal IgG antibodies more accessible for research and diagnostic purposes.
Mammalian Polyclonal IgG Antibody Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- F. Hoffmann-La Roche Ltd
- Bio-Rad Laboratories, Inc.
- Thermo Fisher Scientific
- Cell Signaling Technology, Inc.
- Merck KGaA
- Genway Biotech
- BioNTech
- Abcam plc
- LigaTrap
- Creative Diagnostics
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Product |
|
| Breakup by Applications |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Mammalian Polyclonal IgG Antibody Market Overview
3.1 Global Mammalian Polyclonal IgG Antibody Market Historical Value (2017-2023)
3.2 Global Mammalian Polyclonal IgG Antibody Market Forecast Value (2024-2032)
4 Global Mammalian Polyclonal IgG Antibody Market Landscape
4.1 Mammalian Polyclonal IgG Antibody: Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Mammalian Polyclonal IgG Antibody: Product Landscape
4.2.1 Analysis by Type
4.2.2 Analysis by Technology
4.2.3 Analysis by Indication
5 Global Mammalian Polyclonal IgG Antibody Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Mammalian Polyclonal IgG Antibody Market Segmentation
6.1 Global Mammalian Polyclonal IgG Antibody Market by Product
6.1.1 Market Overview
6.1.2 Cardiac Makers
6.1.3 Metabolic Markers
6.1.4 Renal Markers
6.1.5 Others
6.2 Global Mammalian Polyclonal IgG Antibody Market by Applications
6.2.1 Market Overview
6.2.2 ELISA
6.2.3 Immunoturbidometry
6.2.4 Immunoelectrophoresis
6.2.5 Antibody Identification
6.2.6 Immunohistochemistry
6.2.7 Immunocytochemistry
6.2.8 Western Blotting
6.3 Global Mammalian Polyclonal IgG Antibody Market by End User
6.3.1 Market Overview
6.3.2 Hospitals
6.3.3 Diagnostic Centres
6.3.4 Academic and Research Institutes
6.4 Global Mammalian Polyclonal IgG Antibody Market by Region
6.4.1 Market Overview
6.4.2 North America
6.4.3 Europe
6.4.4 Asia Pacific
6.4.5 Latin America
6.4.6 Middle East and Africa
7 North America Mammalian Polyclonal IgG Antibody Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Mammalian Polyclonal IgG Antibody Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Mammalian Polyclonal IgG Antibody Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America Mammalian Polyclonal IgG Antibody Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Mammalian Polyclonal IgG Antibody Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Regulatory Framework
12.1 Regulatory Overview
12.1.1 US FDA
12.1.2 EU EMA
12.1.3 INDIA CDSCO
12.1.4 JAPAN PMDA
12.1.5 Others
13 Patent Analysis
13.1 Analysis by Type of Patent
13.2 Analysis by Publication year
13.3 Analysis by Issuing Authority
13.4 Analysis by Patent Age
13.5 Analysis by CPC Analysis
13.6 Analysis by Patent Valuation
13.7 Analysis by Key Players
14 Grants Analysis
14.1 Analysis by year
14.2 Analysis by Amount Awarded
14.3 Analysis by Issuing Authority
14.4 Analysis by Grant Application
14.5 Analysis by Funding Institute
14.6 Analysis by NIH Departments
14.7 Analysis by Recipient Organization
15 Clinical Trials Analysis
15.1 Analysis by Trial Registration Year
15.2 Analysis by Trial Status
15.3 Analysis by Trial Phase
15.4 Analysis by Therapeutic Area
15.5 Analysis by Geography
16 Funding and Investment Analysis
16.1 Analysis by Funding Instances
16.2 Analysis by Type of Funding
16.3 Analysis by Funding Amount
16.4 Analysis by Leading Players
16.5 Analysis by Leading Investors
16.6 Analysis by Geography
17 Partnership and Collaborations Analysis
17.1 Analysis by Partnership Instances
17.2 Analysis by Type of Partnership
17.3 Analysis by Leading Players
17.4 Analysis by Geography
18 Supplier Landscape
18.1 F. Hoffmann-La Roche Ltd
18.1.1 Financial Analysis
18.1.2 Product Portfolio
18.1.3 Demographic Reach and Achievements
18.1.4 Mergers and Acquisitions
18.1.5 Certifications
18.2 Bio-Rad Laboratories, Inc.
18.2.1 Financial Analysis
18.2.2 Product Portfolio
18.2.3 Demographic Reach and Achievements
18.2.4 Mergers and Acquisitions
18.2.5 Certifications
18.3 Thermo Fisher Scientific
18.3.1 Financial Analysis
18.3.2 Product Portfolio
18.3.3 Demographic Reach and Achievements
18.3.4 Mergers and Acquisitions
18.3.5 Certifications
18.4 Cell Signaling Technology, Inc.
18.4.1 Financial Analysis
18.4.2 Product Portfolio
18.4.3 Demographic Reach and Achievements
18.4.4 Mergers and Acquisitions
18.4.5 Certifications
18.5 Merck KGaA
18.5.1 Financial Analysis
18.5.2 Product Portfolio
18.5.3 Demographic Reach and Achievements
18.5.4 Mergers and Acquisitions
18.5.5 Certifications
18.6 Genway Biotech
18.6.1 Financial Analysis
18.6.2 Product Portfolio
18.6.3 Demographic Reach and Achievements
18.6.4 Mergers and Acquisitions
18.6.5 Certifications
18.7 BioNTech
18.7.1 Financial Analysis
18.7.2 Product Portfolio
18.7.3 Demographic Reach and Achievements
18.7.4 Mergers and Acquisitions
18.7.5 Certifications
18.8 Abcam plc
18.8.1 Financial Analysis
18.8.2 Product Portfolio
18.8.3 Demographic Reach and Achievements
18.8.4 Mergers and Acquisitions
18.8.5 Certifications
18.9 LigaTrap
18.9.1 Financial Analysis
18.9.2 Product Portfolio
18.9.3 Demographic Reach and Achievements
18.9.4 Mergers and Acquisitions
18.9.5 Certifications
18.10 Creative Diagnostics
18.10.1 Financial Analysis
18.10.2 Product Portfolio
18.10.3 Demographic Reach and Achievements
18.10.4 Mergers and Acquisitions
18.10.5 Certifications
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market attained a value of about USD 1.16 billion in 2023, driven by the increasing genetic research.
The market is anticipated to grow at a CAGR of 5.3% during the forecast period of 2024-2032 and reach a market value of USD 1.84 billion by 2032.
The increasing importance of personalised treatment choices and the increasing prevalence of chronic and infectious diseases are among the major factors driving the demand for mammalian polyclonal IgG antibody in the market.
Increasing studies on potential uses of mammalian polyclonal IgG antibody to find potential clinical solutions against various viruses and clinical conditions is among the major key trends influencing the market demand.
The major regions of the market include North America, Europe, Asia Pacific, Latin America, Middle East and Africa. North America is currently leading the global market.
The products in the market include cardiac makers, metabolic markers, and renal markers, among others.
Mammalian Polyclonal IgG Antibody find wide application in ELISA, immunoturbidometry, immunoelectrophoresis, antibody identification, immunohistochemistry, immunocytochemistry, and western blotting.
The end users in the market include hospitals, diagnostic centres, academic and research institutes.
Key players involved in the market are F. Hoffmann-La Roche Ltd, Bio-Rad Laboratories, Inc., Thermo Fisher Scientific, Cell Signaling Technology, Inc., Merck KGaA, Genway Biotech, BioNTech, Abcam plc, LigaTrap, and Creative Diagnostics.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER